Login | Register
 Username 
 Password 
 
Login

HIV ATLAS

HIV :: TUBERCULOSIS :: MALARIA

Primary links

  • HOME
    • About Us
    • Contact Us
  • CLASSIFIED BLOGS
  • JOBS
  • EVENTS
  • LINKS
  • DAILY WIRE
  • VIDEOS
  |  
Home Blogs bob's blog

Featured Jobs

  • Dean - Indian Institute of Advanced Nursing, Chennai
  • Research Capacity Building Advisor, Haiti
  • Vacancy announcement in Afghanistan
  • Chief of Party- Kenya Public Health
  • Chief of Party/Technical Advisor, HIV-Haiti
  • DEPUTY CHIEF OF PARTY, RUSSIA
  • CHIEF OF PARTY, RUSSIA
  • Chief of Party, India
  • Chief of Party- Kenya
  • Namibia Department of Defense Program Lead

Events

  • Media Outlets Interview Shah During Life Sciences Conference In Seattle
  • First summit of religious leaders on AIDS in Netherlands - Sify
  • Business leaders meet on HIV - Times LIVE
  • 11th International Workshop on Adverse Drug Reactions & Co-Morbidities in HIV Philadelphia, PA, USA, 28 October 2009 (AEGiS)
  • Aids in Culture VI: Explorations in the Cultural History of AIDS International Conference. Mexico City, 9 - 14 December 2010
  • Sexual Health Conference in Bali, May 4-6
  • CBCP calls for summit on HIV-AIDS - ABS CBN News
  • ASEAN youth meet to map out HIV/AIDS prevention activities - Xinhua
  • Gujarat - Get togehter 3000 PLHAs at Capital of Gujarat
  • International Symposium on HIV & Emerging Infectious Diseases.

Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Saf

Submitted by bob on Sat, 07/04/2009 - 17:23
  • Abstracts and Research
  • World Wide

Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection. - Related Articles
Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection.
J Infect Dis. 2009 Aug 1;200(3):337-46
Authors: Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG,
Background. To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals). Methods. In a double-blind, randomized trial, 102 healthy volunteers were evenly allocated to receive RTS,S/AS01B or RTS,S/AS02A vaccine at months 0, 1, and 2 of the study, followed by malaria challenge. Protected vaccine recipients were rechallenged 5 months later. Results. RTS,S/AS01B and RTS,S/AS02A were well tolerated and were safe. The efficacy of RTS,S/AS01B and RTS,S/AS02A was 50% (95% confidence interval [CI], 32.9%-67.1%) and 32% (95% CI, 17.6%-47.6%), respectively. At the time of initial challenge, the RTS,S/AS01B group had greater circumsporozoite protein (CSP)-specific immune responses, including higher immunoglobulin (Ig) G titers, higher numbers of CSP-specific CD4(+) T cells expressing 2 activation markers (interleukin-2, interferon [IFN]-gamma, tumor necrosis factor-alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group. Protected vaccine recipients had a higher CSP-specific IgG titer (geometric mean titer, 188 vs 73 mug/mL; [Formula: see text]), higher numbers of CSP-specific CD4(+) T cells per [Formula: see text] CD4(+) T cells (median, 963 vs 308 CSP-specific CD4(+) T cells/[Formula: see text] CD4(+) T cells; [Formula: see text]), and higher numbers of ex vivo IFN-gamma ELISPOTs (mean, 212 vs 96 spots/million cells; [Formula: see text]). At rechallenge, 4 of 9 vaccine recipients in each group were still completely protected. Conclusions. The RTS,S/AS01B malaria vaccine warrants comparative field trials with RTS,S/AS02A to determine the best formulation for the protection of children and infants. The association between complete protection and immune responses is a potential tool for further optimization of protection. Trial registration. ClinicalTrials.gov identifier NCT00075049 .
PMID: 19569965 [PubMed - in process]
[PubMed-Malaria]

  • bob's blog
  • Login or register to post comments
  • Printer-friendly version

RESOURCES

  • AEGiS
  • AIDS.gov
  • AIDS_ASIA
  • AIDS-INDIA
  • AIDSPORTAL.org
  • About.com
  • Aids-write.org
  • All Africa.com
  • CDC
  • Children & HIV
  • Clinical Care Options HIV
  • DailyMed
  • EATG
  • EBLING LIBRARY
  • Eldis-Jobs
  • Eldis.org
  • GNP Latest news
  • Google-Homophobia
  • Google-HIV Baby-sitting
  • Google HIV NEWS
  • Google MALARIA NEWS
  • Google TB NEWS
  • HIV Law Project
  • HIV Positive Dating
  • HIV Twinning News
  • Hivdatfla
  • Hivsnp
  • IAVI
  • IFANET-INDIA
  • IGIB/CSIR
  • DevNetJobs
  • Indeed.com
  • Iran HIV AIDS
  • Juju-HIV
  • Kaiser-Child health
  • Kaiser HIV/AIDS
  • Kaiser Malaria
  • Kaiser-Tuberculosis
  • Kaiser-U.S. HIV
  • Medical News-HIV
  • Medical News-TB
  • MEDSCAPE
  • Medsin Manchester
  • National AIDS Map
  • Nature Jobs
  • Nets at Harvard University
  • NIAID
  • NMAC
  • NIH.gov
  • NMPrev
  • OpenSource.org.in
  • Oxfam Jobs
  • Partners Zambia
  • Policy and Ethics
  • PozHealth
  • PubMed-HIV
  • PubMed-Malaria
  • RBM Topline Stories
  • SAATHII
  • Save The Children
  • Treatment Action Campaign
  • Tuberculous-Meningitis
  • Tuberculosis-Pulmonary
  • UKLug-HIV
  • UKLug-Tuberculosis
  • UNAIDS-JOBS
  • UNAIDS-SERVICE
  • UNICEF News
  • UNICEF Photo Essays
  • WHO
  • Women & HIV
Every 9½ minutes someone in the US is infected with HIV. Act Against AIDS. Get the facts: NineAndaHalfMinutes.org

ABOUT HIV ATLAS

A Social Media initiative that aims to Collect, Collate, Classify and Disseminate the information on HIV, TB & Malaria so that people living with HIV and the people working in the field can be on top of the information generating from more than 700 online and offline resources.

HIV ATLAS provides its users a unique way to be on top of information ranging from common living to funding, jobs, events and much more absolutely free of charge. We encourage Employers to post their Job opportunities in our featured Jobs cateogry to reach out to more than 40000 subscribers daily.

JOIN HIV ATLAS

HIV ATLAS welcomes content contributions and strongly encourages all sector participants to actively share their advertisements.

You can contribute and engage by:
- Creating your profile
- Posting your classified advertisements
- sharing information about Jobs, Events, Funding etc with us
- sharing information about any online resource you want us to include
- creating your resume for potential employers to have a look in.

NEWLETTER SUBSCRIPTIONS

Manage your newsletter subscriptions
Select the newsletter(s) to which you want to subscribe or unsubscribe.
  Copyright © 2004-2009 HIV ATLAS.org. All rights reserved. | Legal | Contact Powered by Halosys Technologies Inc.  

Disclaimer: This site contains HIV prevention messages that may not be appropriate for all audiences.